Exogenous testosterone in women enhances and inhibits competitive decision-making depending on victory–defeat experience and trait dominance

Pranjal H. Mehta a,⁎, Veerle van Son b, Keith M. Welker c, Smriti Prasad a, Alan G. Sanfey b, Ale Smidts d, Karin Roelofs b

a University of Oregon, 1227 University of Oregon, Eugene, OR 97403, USA
b Radboud University, Donders Institute for Brain, Cognition and Behaviour, Centre for Cognitive Neuroimaging, Kapittelweg 29, Nijmegen 6525 EN, The Netherlands
c University of Colorado Boulder, Department of Psychology, 325 UCB, Boulder, CO 80309, USA
d Erasmus University, Postbus 1738, Rotterdam 3000 DR, The Netherlands

A R T I C L E   I N F O

Article history:
Received 11 June 2015
Received in revised form 7 July 2015
Accepted 7 July 2015

Keywords:
Testosterone
Competition
Dominance
Victory
Defeat
Decision-making

A B S T R A C T

The present experiment tested the causal impact of testosterone on human competitive decision-making. According to prevailing theories about testosterone’s role in social behavior, testosterone should directly boost competitive decisions. But recent correlational evidence suggests that testosterone’s behavioral effects may depend on specific aspects of the context and person relevant to social status (win–lose context and trait dominance). We tested the causal influence of testosterone on competitive decisions by combining hormone administration with measures of trait dominance and a newly developed social competition task in which the victory–defeat context was experimentally manipulated, in a sample of 54 female participants. Consistent with the hypothesis that testosterone has context- and person-dependent effects on competitive behavior, testosterone increased competitive decisions after victory only among high-dominant individuals but testosterone decreased competitive decisions after defeat across all participants. These results suggest that testosterone flexibly modulates competitive decision-making depending on prior social experience and dominance motivation in the service of enhancing social status.

© 2015 Elsevier Ltd. All rights reserved.

Testosterone is theorized to play a role in behaviors implicated in the pursuit of social status, such as competitive behavior (Mazur and Booth, 1998), but the precise role of this hormone in human social behavior remains controversial. One key limitation is that this body of research is comprised primarily of correlational studies. To date, it remains unknown whether testosterone has a causal influence on human competitive decision-making, and if so, the precise nature of that influence. To identify the causal impact of testosterone on human competitive behavior, the present study combined hormone administration, measures of trait dominance, and a newly developed social competition task in which the context was experimentally manipulated. This novel design allowed us to gain a mechanistic understanding about the nature of testosterone’s influence on competitive decision-making.

Prevailing theories suggest that testosterone should directly boost competitive and dominant behaviors during periods of social competition or challenge (Wingfield et al., 1990; Mazur and Booth, 1998; Archer, 2006). Consistent with this challenge hypothesis is evidence that higher testosterone is positively related to aggressive and dominant behaviors across a variety of non-human animal species, especially during times of social instability (Wingfield et al., 1990; Muller and Wrangham, 2004; Archer, 2006; the biosocial model of status makes similar predictions, Mazur and Booth, 1998; see also Terburg and van Honk, 2013). Support for the challenge hypothesis has also emerged in human studies as well. Indeed, a compelling line of research demonstrates that testosterone administration enhances neural, attentional, and behavioral responses to social signals of dominance threat (e.g., angry faces, Hermans et al., 2008; Bos et al., 2012; Terburg et al., 2012; Terburg and van Honk, 2013; Goetz et al., 2014; Enter et al., 2014; Radke et al., 2015).

Other studies suggest that testosterone administration influences psychological processes implicated in dominance motivation, such as reduced trust and empathy (Hermans et al., 2006; Van Honk et al., 2013). Relationships between testosterone and social dominance are less clear, with some studies demonstrating that women with higher levels of testosterone show lower social dominance (Hermans et al., 2006; Van Honk et al., 2013). In contrast, other studies have shown that women with higher levels of testosterone report higher levels of social dominance (Hermans et al., 2006; Van Honk et al., 2013).

⁎ Corresponding author at: Department of Psychology, University of Oregon, Eugene, OR 97403, USA.
E-mail address: mehta@uoregon.edu (P.H. Mehta).

http://dx.doi.org/10.1016/j.psyneuen.2015.07.004
0306-4530/© 2015 Elsevier Ltd. All rights reserved.
However, inconsistencies have also begun to accumulate in other research on testosterone and human social behavior (Mazur and Booth, 1998; Archer, 2006; Eisenegger et al., 2011; Carré and Olmstead, 2015). For example, the few human studies that investigated exogenous testosterone’s influence on status-relevant behaviors such as bargaining behaviors or aggression have revealed inconsistent results (e.g., Eisenegger et al., 2009; Zak et al., 2009; Zethraeus et al., 2009; for relevant review see Eisenegger et al., 2011). Although these studies of bargaining behavior used different methods to exogenously administer testosterone and different populations (Eisenegger et al., 2009: female participants with an average age of 25.16 years in Switzerland who were administered a single dose of testosterone sublingually; Zak et al., 2009: male participants with an average age of 20.8 years in the United States who were given Androgel®; Zethraeus et al., 2009: postmenopausal women in Sweden between the ages of 50–65 who were administered testosterone undecanoate daily for four weeks), it remains unclear what factors account for the heterogeneous results across these studies. Collectively, prior research lends some support for the hypothesis that testosterone may enhance competitive and dominant behaviors, but there are many inconsistent findings.

These inconsistencies may arise because testosterone’s role in status-relevant behavior could depend on key aspects of the context and the person relevant to social status. Consistent with this possibility, several correlational studies reveal that testosterone’s role in status-relevant behavior depends on one specific contextual factor: whether a prior dominance contest resulted in victory or defeat (Newman et al., 2005; Schultheiss et al., 2005; Josephs et al., 2006; Mehta and Josephs, 2006; Mehta et al., 2008; Carré et al., 2009, 2013). In a study of undergraduate females for example, high basal testosterone was associated with increased competitive behavior after victory and decreased competitive behavior after defeat (Mehta et al., 2008). These results suggest that higher testosterone is related to a drive to attain high status and leads to heightened reactions to rises/drops in status (victory/defeat) within the dominance hierarchy. Higher testosterone predicts increased competitive behavior after victory presumably to reinforce one’s higher status position in the hierarchy, whereas higher testosterone predicts reduced competitive behavior after defeat presumably to avoid further loss of status in the hierarchy (Mehta et al., 2008). Yet other correlational studies that also accounted for wins versus losses and measured testosterone showed different results (e.g., null direct associations between testosterone and behavior after victory, Mehta and Josephs, 2006; Carré et al., 2009). These inconsistencies suggest that there is unexplained variability in testosterone’s behavioral effects that cannot be accounted for by the victory–defeat context alone.

A possible explanation for these heterogeneous findings is that testosterone’s role in status-relevant behavior may not only be context-dependent (prior victory–defeat experience) but may also be person-dependent. Trait dominance assesses a person’s self-reported motivation to attain high status positions but does not strongly correlate with endogenous testosterone (Jackson, 1967; Josephs et al., 2006). Researchers have theorized that testosterone is an unconscious marker of dominance motivation (Terburg et al., 2012) that interacts with consciously experienced, self-reported dominance motivation to influence status-relevant behaviors (Slatcher et al., 2011). Consistent with this theorizing, two correlational studies found that testosterone’s associations with mating and aggressive behaviors were stronger among individuals high in self-reported trait dominance. In one study, men reported to the lab in pairs, completed a self-report trait dominance scale, provided saliva samples for testosterone measurement, and engaged in a seven-minute videotaped social interaction with the other male participant as well as an attractive female confederate (Slatcher et al., 2011). The men were led to believe that this woman was another participant and that she would choose which of the two men she “clicked” with better. Results revealed a null association between endogenous testosterone and self-reported trait dominance, which is consistent with evidence that testosterone influences dominance motivation outside of consciousness (Josephs et al., 2006; Terburg et al., 2012). Instead, endogenous testosterone interacted with self-reported trait dominance to predict men’s dominant mating behaviors (e.g., taking control of the interaction, talking about himself). There was a positive association between testosterone and dominant mating behaviors only among men high in trait dominance, but not among men low in trait dominance. In a second study, participants completed a trait dominance questionnaire, were randomly assigned to win or lose in a cognitive contest, provided saliva samples before and after the competition to assess changes in testosterone concentrations, and then completed a task that measures aggressive behavior (Carré et al., 2009). Results revealed that endogenous testosterone interacted with trait dominance in the victory condition only, a social experience indicative of a more dominant position in the hierarchy. A rise in testosterone after victory was related to increased aggressive behavior only among men high in trait dominance but not among men low in trait dominance. These two correlational studies suggest that testosterone is positively related to mating and aggressive behaviors among men high in trait dominance, especially after a victory experience. However, no studies to date have investigated whether testosterone interacts with trait dominance and prior victory–defeat experience to predict competitive decision-making.

Taken together, these recent studies lend some indirect support for the hypothesis that testosterone’s influence on competitive behavior should depend on status-relevant aspects of both the context (prior win–lose experience) and the person (trait dominance). However, the indirect evidence for this hypothesis has been derived exclusively from correlational data, and results are inconsistent across studies. To date, it remains unknown to what extent testosterone has a causal impact on human competitive decision-making, and if so, whether this hormonal influence on behavior depends on specific context- and person-factors implicated in social status (win–lose context and trait dominance). Research that delineates the causal pathway between testosterone and competitive decisions is critical to elucidating the neuroendocrine mechanisms of status-relevant behavior, but pharmacological studies that test this causal pathway are lacking. We designed a study in which hormone concentrations and the social context were experimentally manipulated in order to address these open questions regarding testosterone’s causal role in competitive behavior.

1 Carré et al. (2009) reported null associations between endogenous testosterone and aggressive behavior in women (non-significant main effect and non-significant testosterone × trait dominance interactions), but these null effects may have emerged because of lower measurement validity for salivary testosterone in females (Giangre et al., 2004), because women may be less likely to employ aggression as a means for status attainment (e.g., Archer, 2009), or because of low statistical power (data from 50 women used in the main analyses). We return to the issue of potential sex differences in testosterone’s behavioral effects in the discussion.
tive decision. Our primary analyses tested the causal impact of testosterone administration on competitive decision-making and whether this hormonal influence on behavior depended on prior victory–defeat experience and trait dominance, two factors relevant to the pursuit of social status. These research questions build directly on prior correlational studies, which demonstrate that testosterone’s association with status-relevant behavior varies as a function of prior victory–defeat experience and trait dominance (e.g., Mehta et al., 2008; Carré et al., 2009; Slater et al., 2011).

Besides experimentally manipulating the win–lose context, we also manipulated opponent social rank in the competitive task. Participants competed against lower-ranking, same-rank, and higher-ranking opponents in multiple competitive bouts. Win–lose experience has received substantial empirical attention in prior correlational research on testosterone and competition, but opponent rank has received little empirical attention in this literature even though this factor is related to psychological theories of social hierarchy. The few correlational studies that examined features of the opponent such as opponent skill found some inconsistent associations with testosterone concentrations (e.g., Bateup et al., 2002; Neave and Wolfson, 2003; see also Salvador, 2005; van der Meij et al., 2010), but no prior study to our knowledge has investigated whether testosterone interacts with opponent rank to predict status-relevant behaviors such as competitive decision-making. Thus, we conducted follow-up exploratory analyses to determine the extent to which exogenous testosterone’s influence on competitive behavior does or does not depend on the opponent’s rank.

2. Methods

2.1. Participants

Fifty-four healthy females recruited at Radboud University Nijmegen participated in the experiment in exchange for monetary compensation. The protocol was approved by the ethics committee at Radboud University. The age range was restricted to control for potential age-related changes in hormone concentrations (age range = 18–30 years, M = 21.6, SD = 2.4). Participants had no history of psychiatric, neurological, or endocrine disease and were not current using corticosteroids. Only women were studied in the present experiment because the pharmacokinetics of this testosterone administration technique have been well-established in women but not in men (Tuiten et al., 2000), and this decision is in keeping with the bulk of prior testosterone administration studies that have adopted this same dosage and sublingual administration technique (Eisenegger et al., 2011; Bos et al., 2012). Our study design builds upon this existing well-established body of research. We included only women who were taking hormonal contraceptives in order to control potential fluctuation in testosterone concentrations across the menstrual cycle. The distribution in hormonal contraceptive was as follows: oral (44 women), hormonal IUD (Mirena) (8 women), progesterone implant (Nuvaring) (1 woman), and Implanon (1 woman). During a phone conversation to schedule participants in experimental sessions, participants were instructed not to sign up for experimental sessions during the stop week (when there was no active contraception).

2.2. Procedure

2.2.1. Informed consent and baseline saliva sample

Experimental sessions were scheduled to begin at 1000 h or 1130 h to control for circadian rhythms in hormone concentrations. Participants were given an electronic copy of the consent form prior to arrival at the laboratory. Upon arrival, participants were again explained the procedures and provided informed consent. Next standard collection procedures were used to assess endogenous salivary testosterone concentrations (Schultheiss and Stanton, 2009). Participants provided 2.5 mL of saliva in a sterile polypropylene microtube. The samples were immediately transported to a freezer for long-term storage.

2.2.2. Testosterone administration

Participants then self-administered a single dose of either testosterone or placebo solution sublingually in a double-blind between-subjects design. The testosterone dose consisted of 0.5 mg of testosterone suspended in a clear solution with 0.5 mg of hydroxypropyl–β-cyclodextrin, 0.005 mL of 96% ethanol, and distilled water. The presence or absence of testosterone was the only difference between the testosterone and placebo solutions. Previous research in which 0.5 mg of testosterone was administered sublingually in women established the pharmacokinetics of this dosage and testosterone administration technique (Tuiten et al., 2000). Specifically, there was a tenfold increase in serum testosterone levels within 15 min after administration and a return to baseline within 90 min. However, physiological and psychological effects did not peak until approximately 4–6 h after administration. Several pharmacology studies that adopted this dosage and administration technique in females followed by a 4–6 h delay detected robust psychological and behavioral effects (for relevant reviews, see Eisenegger et al., 2011; Bos et al., 2012). Hence, the behavioral testing session in the present experiment began approximately 4.5 h after testosterone or placebo administration.

2.2.3. Trait dominance

Within one hour after the testosterone versus placebo administration, participants completed the Personality Research Form Need for Power scale, a well-validated self-report measure of dominance that contains 16 true–false items (Jackson, 1967). Eight of the items are reverse-coded. Example items include “I try to control others rather than permit them to control me,” and “I avoid positions of power over other people.” (reverse-coded). This scale has been used in prior research on endogenous testosterone and its interactions with self-reported dominance (Slatcher et al., 2011). Scores on this scale can range from 0 to 16 and did so in the present study (M = 6.47, SD = 3.69). As reported above, psychological effects of this sublingual testosterone administration technique are not expected until approximately 4–6 h after administration (Tuiten et al., 2000). Consistent with this evidence, testosterone administration in the present experiment did not influence scores on this self-reported dominance scale compared to placebo (F(1,49) = 0.13, p = 0.73, n² partial = 0.003. This evidence indicates that these scores represent trait levels of dominance and do not reflect changes in self-reported dominance motivation in response to the pharmacological manipulation.

2.2.4. Dot estimation competitive task

Participants completed a newly developed dot estimation competitive task, which was inspired by prior research on testosterone, competition, and social hierarchies (Mehta et al., 2008; Zink et al., 2008). This novel social competition task was designed to experimentally manipulate prior win–lose experience in a within-subjects design and measure competitive decision-making in response to the manipulation. This design allowed us to test whether exogenous testosterone’s influence on competitive decisions depends on the victory–defeat context and trait dominance. This win–lose context manipulation was included to test our main hypotheses, but we also included an exploratory manipulation of the opponent’s social rank on the task (Zink et al., 2008) – either a high-ranking (three-star-player), medium-ranking (two-star player), or low-ranking opponent (one-star player) – to explore
whether this contextual factor also moderates the influence of testosterone on competitive behavior.

Participants were told that they would be completing a competitive dot estimation in two phases: Phase 1—the New Opponents Phase, and Phase 2—the Re-Challenge phase, and that the goal of the task is to estimate the number of dots on the screen as quickly and accurately as possible. They were informed that they would compete against 90 other women in Phase 1, and that these women had previously completed the task and were grouped into three categories based on task performance: one-star players (lowest performing), two-star players (middle performing), and three-star players (highest performing). Participants were further told that they were being assigned a two-star player ranking for now, but that this rank would be updated at the end of Phase 1 and 2. Thus, this paradigm was designed to model an unstable social hierarchy (Zink et al., 2008).

In Phase 1 of the task, participants competed on 90 trials of a cognitive dot estimation task ostensibly against these 90 other women who had previously completed the task and had been ranked based on their performance. A trial of the task is shown in Fig. 1. In each trial, participants had four seconds to estimate the number of dots that appeared on the screen as accurately and quickly as possible, based on four choices. Participants selected the response that was closest to their estimate with a button press corresponding to their choice. Although participants were led to believe they were competing with other female opponents who had previously completed the task, in reality the task was pre-programmed. The dot estimation problem seen in each round was randomized (Mean number of dots in each trial = 41, SD = 17), and we experimentally manipulated the outcome of the competition such that participants received feedback that they either won or lost against the other opponent (45 win trials, 45 lose trials) presented in randomized order. Opponent rank (30 trials against one-star player, 30 trials against two-star players, 30 trials against three-trials players) was also experimentally manipulated and randomized across the 90 trials of the task. These experimental manipulations resulted in six task conditions for each participant: 15 victory trials against one-star players, 15 victory trials against two-star players, 15 victory trials against three-star players, 15 defeat trials against one-star players, 15 defeat trials against two-star players, 15 defeat trials against three-star player.

After receiving feedback that they had either won or lost the competition, participants then decided whether to (a) compete again against the same opponent on a new dot estimation problem, or (b) complete a practice dot estimation problem without competing (Mehta and Josephs, 2006; Carré and McCormick, 2008; Mehta et al., 2008). Participants decided whether to compete again or not (“Yes” or “No”) with a button press corresponding to their choice. Participants were told that these additional rounds of competition or non-competition would occur in “Phase 2—the Re-Challenge Phase.”
2.2.5. Affect
Self-reported state positive and negative affect was measured with the Positive and Negative Affect Schedule (PANAS, Watson et al., 1988) at baseline prior to testosterone/placebo administration, four hours later prior to behavioral testing, and at the very end of the experiment. The primary goal of the current experiment was to test the causal impact of testosterone on competitive decisions, but these behavioral effects may potentially be influenced by affective responses to testosterone treatment. Indeed, some studies have shown mood-enhancing effects of testosterone administration (Amanatkar et al., 2014) and theories suggest that positive affect may influence competitive, approach-orientated behaviors (Keltner et al., 2003). Thus, we conducted analyses in which we controlled affective responses to testosterone treatment. An effect of testosterone treatment on competitive decisions when controlling for affect would rule out mood changes as an alternative explanation for our results.

2.2.6. Beliefs about pharmacological manipulation and suspicion check
In line with prior research (e.g., Eisenegger et al., 2009), we measured whether participants believed they received testosterone or placebo treatment at the very end of the experiment with a forced choice question (“Do you think you received testosterone or placebo? If you are not sure, please guess. Circle your response.”). Participants also filled out open-ended questions regarding the dot estimation to assess their suspicion with the task (e.g., “Did you think anything about the dot estimation task was odd? If so, please describe.”; Mehta and Josephs, 2006; Mehta et al., 2008). Three participants reported that they did not believe that they were competing against real people in the dot estimation task. Therefore, these three participants were excluded from our statistical analyses.

2.2.7. Hormone assays
After data collection in the study was complete, saliva samples were shipped on dry ice to Clemens Kirschbaum’s laboratory in Dresden, Germany. Saliva samples were analyzed for testosterone in duplicate using a double-antibody luminescence immunoassay kit (RE62031; IBL International, Hamburg, Germany). The average inter-assay coefficient of variation was 6.48%, and the average intra-assay coefficient of variation was 8.56%. As expected, baseline testosterone concentrations were not statistically different in the experimental groups (testosterone group: $M = 22.11$ pg/mL, $SD = 11.74$; placebo group: $M = 22.52$ pg/mL, $SD = 15.00$, t(49) = −0.11, p = 0.92).

2.3. Statistical analysis strategy
Our primary statistical analyses tested the extent to which testosterone treatment influenced competitive decisions and whether this hormonal influence on decision-making depended on the victory–defeat context and trait dominance. These research questions build on prior correlational studies in which testosterone interacted with prior victory–defeat experience and trait dominance to predict status-relevant behavior (e.g., Mehta et al., 2008; Carré et al., 2009; Slatcher et al., 2011). We used multilevel models to test these questions. As noted by statisticians, multilevel models have advantages in studies when predictor variables are measured or manipulated at more than one level, such as victory versus defeat trial types (Level 1) nested within participants (Level 2) (Garson, 2012). The predictors in our multilevel model were competition outcome (0 = defeat, 1 = victory) as a within-subjects (Level 1) factor along with the Level 2 factors of Testosterone condition (0 = placebo, 1 = testosterone) and Trait Dominance (centered), plus all interaction terms. The dependent variable was the percentage of trials in which participants chose to compete again. We also added change in positive affect as a covariate to the model in order to rule out testosterone-induced affective changes as an alternative explanation for our results. To interpret a significant Testosterone × Win–Lose Context × Trait Dominance interaction, we employed the Aiken and West (1991) approach in which the intercept and slope estimates from the multilevel model were used to graph competitive decisions after victory and defeat one standard deviation above and below the mean for trait dominance in the placebo and testosterone groups. For an overview of interpreting statistical interactions, see Aiken and West (1991). Below we describe three follow-up analytical approaches that were used to further investigate the three-way interaction.

2.3.1. Separate analyses of victory and defeat trials
We conducted follow-up multilevel analyses in which we examined the effects of Testosterone condition, Trait Dominance, and their interaction as predictors of competitive decisions separately for victory and defeat trials. This approach allows us to compare our results to prior correlational studies that experimentally manipulated victory–defeat context in between-subjects designs and reported separate hormone-behavior results for victory and defeat (e.g., Carré et al., 2009).

2.3.2. Median split analyses
Although researchers sometimes examine interaction effects by converting continuous variables into categories (e.g., median splits), this technique has significant drawbacks and therefore is not recommended by statisticians (Aiken and West, 1991; Maxwell and Delaney, 1993; Altman and Royston, 2006; MacCallum et al., 2002; Fitzsimons, 2008). One drawback is that the researcher loses information when grouping continuous variables into categories. For example, if a median split is performed on trait dominance levels, then an individual just above the median on trait dominance is considered the same as an individual at the very end of the trait dominance distribution. A second drawback is the loss of statistical power with this approach. Despite the weaknesses of this statistical approach, in follow-up analyses we conducted median splits on trait dominance scores to determine whether the same pattern of results remained. We included these analyses because we reasoned that they may be easier to interpret for readers unfamiliar with interpreting interactions in multilevel or standard regression models.

2.3.3. Competitive decisions after victory compared to defeat within individuals
Because the win–lose context manipulation is a within-subjects factor, we also ran analyses in which we directly compared behavioral responses to victory and defeat trials within the same individual. More specifically, we tested whether competitive behavior after victory compared to defeat varied as a function of testosterone condition and trait dominance scores. We conducted simple slopes analyses (Aiken and West, 1991) in which the parameter estimates from the multilevel analyses were used to test whether there were statistically significant differences in behavioral responses to victory versus defeat one standard deviation above and below the mean on trait dominance for the testosterone and placebo groups.

To further investigate these within-individual behavioral responses to victory versus defeat, we conducted a follow-up multiple-regression analysis in which the dependent variable was the percentage of win trials in which participants chose to compete minus the percentage of loss trials in which participants chose to compete. A positive score indicates that the participant showed a greater propensity to compete again after a victory experience compared to a defeat experience. For example, a participant who
chose to compete on 80% of victory trials and 40% of defeat trials would have score of 40 on this dependent measure (80–40). The key predictors in this analysis were Testosterone condition (0 = Placebo Treatment, 1 = Testosterone Treatment), Trait Dominance (centered), and the Testosterone × Trait Dominance interaction. This statistical approach in which the dependent variable is a difference score is widely employed in studies with repeated measures factors and simplifies interpretation (e.g., studies in which testosterone is exogenous administered in a within-subjects design, Montoya et al., 2013). To interpret a significant Testosterone × Trait Dominance interaction, we conducted simple slopes analyses in which the regression model intercept and slopes were used to compare the effect of testosterone versus placebo treatment on competitive decisions one standard deviation above and below the mean for trait dominance (Aiken and West, 1991).

2.3.4. Testosterone and opponent rank

Our main research questions examined the extent to which testosterone interacted with the prior win–lose experience and trait dominance to modulate competitive behavior, but we conducted exploratory analyses in which we tested whether exogenous testosterone’s impact on competitive decisions also depended on opponent rank. We added Opponent Rank an additional factor to a multilevel analysis. The predictors in this analysis were Opponent Rank (Lower-ranked, Same-ranked, or Higher-Ranked player) and Competition Outcome (Win or Loss) as within-subjects (Level 1) factors, along with the Level 2 factors of Testosterone condition (0 = placebo, 1 = testosterone) and Trait Dominance (centered), plus all interaction terms. The dependent variable was the percentage of trials in which participants chose to compete again.

2.3.5. Baseline testosterone and beliefs about the pharmacological manipulation

Finally, we conducted additional analyses to confirm that our results held up when accounting for endogenous baseline testosterone concentrations or beliefs about the pharmacological manipulation.

3. Results

3.1. Descriptive statistics and preliminary analyses

Table 1 reports descriptive statistics for the full sample and separately for participants in the testosterone and placebo groups. Table 2 reports competitive decisions as a function of our two within-subjects experimental manipulations (win–lose experience and opponent rank). There were non-significant differences in trait dominance and baseline testosterone between the testosterone and placebo groups (p > 0.10). There were also non-significant effects of testosterone treatment on negative affect (p > 0.05), but testosterone treatment increased positive affect compared to placebo from baseline to the end of the experiment (F(2,98) = 4.15, p < 0.05; r partial = 0.24; M = -4.63, SD = 3.20; testosterone group: M = -2.00, SD = 3.96). Hence, we included change in positive affect as a covariate in our primary analyses in order to rule out testosterone-induced mood changes as an alternative explanation for the results (see below).

Table 1
Descriptive statistics for main study measures.

<table>
<thead>
<tr>
<th></th>
<th>Full sample (n = 51)</th>
<th>Placebo group (n = 27)</th>
<th>Testosterone group (n = 24)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>M</td>
<td>SD</td>
<td>M</td>
</tr>
<tr>
<td>Trait dominance a</td>
<td>6.47</td>
<td>3.69</td>
<td>6.30</td>
</tr>
<tr>
<td>Baseline testosterone (pg/mL)</td>
<td>22.33</td>
<td>13.44</td>
<td>22.52</td>
</tr>
<tr>
<td>Positive affect time 1 b</td>
<td>24.59</td>
<td>3.91</td>
<td>24.33</td>
</tr>
<tr>
<td>Positive affect time 2 b</td>
<td>24.12</td>
<td>4.20</td>
<td>23.56</td>
</tr>
<tr>
<td>Positive affect time 3 b</td>
<td>21.20</td>
<td>4.61</td>
<td>19.70</td>
</tr>
<tr>
<td>Negative affect time 1 b</td>
<td>15.73</td>
<td>3.20</td>
<td>14.85</td>
</tr>
<tr>
<td>Negative affect time 2 b</td>
<td>15.45</td>
<td>2.98</td>
<td>15.26</td>
</tr>
<tr>
<td>Negative affect time 3 b</td>
<td>15.24</td>
<td>3.12</td>
<td>14.85</td>
</tr>
<tr>
<td>Competitive decisions (%)</td>
<td>60.66</td>
<td>20.62</td>
<td>64.10</td>
</tr>
</tbody>
</table>

a Measured with the Personality Research Form Need for Power scale (Jackson, 1967). b Measured with the PANAS (Watson et al., 1988). Time 1 = Baseline prior testosterone/placebo administration; time 2 = Approximately 4 h after testosterone/placebo administration prior to the behavioral testing; time 3: At the conclusion of the experiment.

Table 2
Descriptive statistics for competitive decisions (percentage of trials in which participants chose to compete) as a function of competition outcome (victory versus defeat experience) and opponent rank [lower-ranked opponent, same-ranked opponent, or higher-ranked opponent]. Means are reported followed by standard deviations in parentheses.

<table>
<thead>
<tr>
<th></th>
<th>Lower-ranked opponent</th>
<th>Same-ranked opponent</th>
<th>Higher-ranked opponent</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>M</td>
<td>SD</td>
<td>M</td>
</tr>
<tr>
<td>Entire sample (n = 51)</td>
<td>Victory</td>
<td>73.18 (39.05)</td>
<td>70.50 (40.04)</td>
</tr>
<tr>
<td></td>
<td>Defeat</td>
<td>69.70 (30.30)</td>
<td>58.40 (34.38)</td>
</tr>
<tr>
<td>Placebo group (n = 27)</td>
<td>Victory</td>
<td>74.52 (39.69)</td>
<td>71.21 (40.71)</td>
</tr>
<tr>
<td></td>
<td>Defeat</td>
<td>78.01 (25.33)</td>
<td>65.91 (32.42)</td>
</tr>
<tr>
<td>Testosterone group (n = 24)</td>
<td>Victory</td>
<td>71.67 (39.10)</td>
<td>69.70 (40.13)</td>
</tr>
<tr>
<td></td>
<td>Defeat</td>
<td>60.36 (33.15)</td>
<td>49.94 (35.22)</td>
</tr>
</tbody>
</table>
Inconsistent with the hypothesis that testosterone directly boosts competitive behavior, an independent samples t-test revealed that the testosterone (M = 56.80%, SE = 3.30) and placebo groups (M = 64.10%, SE = 4.56) did not statistically differ in overall rates of competitive decisions (percentage of all trials in which participants chose to compete again; t(49) = 1.27, p = 0.21; Cohen’s d = 0.36). This non-significant direct effect of testosterone on competitive behavior is consistent with recent correlational research (Mehta et al., 2008, 2009; Carré et al., 2009).

3.2. Effects of testosterone treatment, win–lose context, and trait dominance on competitive decisions

Building on prior correlational studies (e.g., Mehta et al., 2008; Carré et al., 2009; Slatcher et al., 2011), our primary analyses tested the extent to which the causal impact of testosterone on competitive decisions depended on the win–lose context and trait dominance. We conducted a moderated multilevel linear model analysis with trial types (Level 1) nested within participants (Level 2). The predictors were competition outcome (0 = defeat, 1 = victory) as a within-subjects (Level 1) factor along with the Level 2 factors of Testosterone condition (0 = placebo, 1 = testosterone) and Trait Dominance (centered), plus all interaction terms. The dependent variable was the percentage of trials in which participants chose to compete again (see Section 2.3 for rationale for this statistical approach). In agreement with the hypothesis that testosterone has context- and person-dependent effects on competitive behavior, this analysis revealed a statistically significant Testosterone Treatment × Competition Outcome × Trait Dominance interaction (b = 29.63, 95% CI [3.96, 55.30], t(47) = 2.32, p = 0.025). In order to rule out testosterone-induced mood change as an alternative explanation for these results, we conducted another multilevel analysis in which change in positive affect was added as a covariate. Once again, the Testosterone Treatment × Competition Outcome × Trait Dominance interaction emerged (b = 29.63, 95% CI [3.96, 55.29], t(47) = 2.32, p = 0.025). The full multilevel model is shown in Table 3. The parameter estimates from the model were used to depict competitive decision-making predicted scores one standard deviation above and below the mean on trait dominance for the testosterone and placebo groups (Fig. 2 Column A; Aiken and West, 1991; see also Section 2.3 for more information on interpreting statistical interactions). We also graphed the effect of testosterone versus placebo on average compete rates after victory and average compete rates after defeat across all participants (ignoring trait dominance scores) (Fig. 2 Column B).

3.2.1. Separate analyses of victory and defeat trials

To interpret the Testosterone × Win–Lose Context × Trait Dominance interaction and determine whether the effects of testosterone on competitive behavior were independent from testosterone-induced changes in positive affect, we conducted follow-up multilevel analyses on competitive decisions for victory and defeat trials separately. This approach also allows us to compare our results to prior correlational studies that conducted separate hormone-behavior analyses in the victory and defeat conditions (e.g., Mehta et al., 2008; Carré et al., 2009). These analyses are reported in Table 4. The first model reported in Table 4 includes positive affect change, Testosterone Condition, Trait Dominance, and the Testosterone × Trait Dominance interaction as predictors of competitive decisions after victory. Consistent with upper panels of Fig. 2, this analysis revealed no main effects and a statistically significant Testosterone × Trait Dominance interaction (b = 23.97, 95% CI [4.28, 43.67], t(46) = 2.45, p = 0.018). As reported in the correlation matrix in Table 5, there was a positive association between trait dominance and competitive decisions after victory in the testosterone group, but this effect did not emerge in the placebo group. This pattern indicates that testosterone treatment increased the propensity to compete again after victory among high-dominant individuals but not among low-dominant individuals. This pattern is highly consistent with the results of a prior correlational study, which also found a Testosterone × Trait Dominance interaction in the victory condition (Carré et al., 2009).

The second model reported in Table 4 includes Positive Affect change, Testosterone Condition, Trait Dominance, and the Testosterone × Trait Dominance interaction as predictors of competitive decisions after defeat. This analysis revealed only a statistically significant main effect of Testosterone (b = −16.86, 95% CI [−33.70, −1.01], t(46) = −2.14, p = 0.038). As shown in Fig. 2, testosterone administration reduced the percentage of trials in which participants chose to compete again after defeat (M = 45.44%, SE = 5.99) compared to placebo (M = 63.34%, SE = 5.62) across all participants. This direct effect of testosterone on reduced competitive decisions after defeat closely overlaps with the results of a prior correlational study, which found that higher endogenous testosterone was related to reduced competitive decisions after defeat (Mehta et al., 2008). The pattern suggests that the effect of testosterone on a decreased propensity to compete again after defeat was stronger among high-dominant individuals, but not significantly so as indicated by the non-significant Testosterone × Trait Dominance interaction. These analyses further elucidate the pattern of the Testosterone × Competition Outcome × Trait Dominance interaction shown in Fig. 2.

Table 3

Multi-level model for competition outcome (Level 1), testosterone treatment (0 = placebo, 1 = testosterone) (Level 2), trait dominance (centered) (Level 2), and all interactions as predictors of competitive decisions (% compete again).

<table>
<thead>
<tr>
<th></th>
<th>B</th>
<th>SE</th>
<th>df</th>
<th>t</th>
<th>p</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Lower</td>
</tr>
<tr>
<td>Constant</td>
<td>71.92</td>
<td>5.90</td>
<td></td>
<td>1.00</td>
<td>0.166</td>
<td>51.15</td>
</tr>
<tr>
<td>Positive affect change</td>
<td>0.37</td>
<td>0.73</td>
<td></td>
<td>0.03</td>
<td>0.988</td>
<td>5.99</td>
</tr>
<tr>
<td>Competition outcome</td>
<td>−2.57</td>
<td>8.84</td>
<td></td>
<td>−0.29</td>
<td>0.773</td>
<td>−46.00</td>
</tr>
<tr>
<td>Testosterone condition</td>
<td>−17.02</td>
<td>7.32</td>
<td></td>
<td>−2.35</td>
<td>0.024</td>
<td>−31.72</td>
</tr>
<tr>
<td>Trait dominance</td>
<td>−6.47</td>
<td>5.16</td>
<td></td>
<td>−1.25</td>
<td>0.216</td>
<td>−16.85</td>
</tr>
<tr>
<td>Testosterone × outcome</td>
<td>12.52</td>
<td>12.90</td>
<td></td>
<td>0.97</td>
<td>0.336</td>
<td>−13.41</td>
</tr>
<tr>
<td>Testosterone × dominance</td>
<td>−4.28</td>
<td>7.00</td>
<td></td>
<td>−0.61</td>
<td>0.544</td>
<td>−18.35</td>
</tr>
<tr>
<td>Competition outcome × dominance</td>
<td>−3.15</td>
<td>9.41</td>
<td></td>
<td>−0.33</td>
<td>0.739</td>
<td>−22.08</td>
</tr>
<tr>
<td>Testosterone × outcome × dominance</td>
<td>29.63</td>
<td>12.76</td>
<td>47.00</td>
<td>2.32</td>
<td>0.025</td>
<td>3.96</td>
</tr>
</tbody>
</table>

Note: The main effect of testosterone condition in this analysis should be interpreted with caution because an independent samples t-test revealed a non-significant effect of testosterone on competitive decisions (see Section 3.1 in the main text) and because this effect was further qualified by a Testosterone × Competition Outcome × Trait Dominance interaction.
Fig. 2. Panel A. Interactive effects of testosterone condition and trait dominance on competitive decisions, following standard procedures for interpreting statistical interactions (Aiken and West, 1991). Panel B. Effects of testosterone versus placebo on competitive decisions after ignoring trait dominance scores. (For interpretation of the references to color in the figure, the reader is referred to the web version of this article.)

Table 4
Follow-up multi-level analyses for testosterone treatment (0 = placebo, 1 = testosterone), trait dominance (centered), and their interaction as predictors of competitive decisions, separately for victory trials and defeat trials.

<table>
<thead>
<tr>
<th>Model 1. Dependent variable: competitive decisions after victory (% compete again)</th>
<th>95% CI</th>
<th>Lower</th>
<th>Upper</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constant</td>
<td>69.25</td>
<td>9.40</td>
<td>50.32</td>
</tr>
<tr>
<td>Positive affect change</td>
<td>0.67</td>
<td>1.41</td>
<td>0.477</td>
</tr>
<tr>
<td>Testosterone condition</td>
<td>-3.21</td>
<td>10.54</td>
<td>-0.304</td>
</tr>
<tr>
<td>Trait dominance</td>
<td>-9.70</td>
<td>7.21</td>
<td>-1.345</td>
</tr>
<tr>
<td>Testosterone × trait dominance</td>
<td>23.97</td>
<td>9.79</td>
<td>2.450</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Model 2. Dependent variable: competitive decisions after defeat (% compete again)</th>
<th>95% CI</th>
<th>Lower</th>
<th>Upper</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constant</td>
<td>71.27</td>
<td>7.02</td>
<td>57.14</td>
</tr>
<tr>
<td>Positive affect change</td>
<td>1.07</td>
<td>1.05</td>
<td>1.019</td>
</tr>
<tr>
<td>Testosterone condition</td>
<td>-16.86</td>
<td>7.87</td>
<td>-2.142</td>
</tr>
<tr>
<td>Trait dominance</td>
<td>-4.42</td>
<td>5.38</td>
<td>-0.822</td>
</tr>
<tr>
<td>Testosterone × trait dominance</td>
<td>-5.76</td>
<td>7.30</td>
<td>-0.788</td>
</tr>
</tbody>
</table>

Table 5
Spearman correlations between trait dominance and measures of competitive decision-making.

<table>
<thead>
<tr>
<th></th>
<th>Full sample</th>
<th>Placebo group</th>
<th>Testosterone group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n = 51)</td>
<td>(n = 27)</td>
<td>(n = 24)</td>
</tr>
<tr>
<td>Competitive decisions after victory (%)</td>
<td>0.08</td>
<td>-0.22</td>
<td>0.45*</td>
</tr>
<tr>
<td>Competitive decisions after defeat (%)</td>
<td>-0.20</td>
<td>-0.14</td>
<td>-0.36†</td>
</tr>
<tr>
<td>Competitive decisions – victory minus defeat (%)</td>
<td>0.19</td>
<td>-0.13</td>
<td>0.47†</td>
</tr>
</tbody>
</table>

* p < 0.05.
† p < 0.10.
3.2.3. Median split analyses

Next we conducted a median split on trait dominance in order to determine whether similar results emerged with this alternative approach. As reviewed earlier median split analyses have significant drawbacks compared to a multiple-regression approach such as reduced statistical power (Aiken and West, 1991; see our Section 2.3 for discussion on some of the drawbacks), but we reasoned that these analyses may be easier to interpret for readers unfamiliar with interpreting interactions in regression or multilevel analyses (for additional limitations of median splits and for more details on recommended approaches for interpreting interactions such as those reported above, see Aiken and West, 1991; Maxwell and Delaney, 1993; MacCallum et al., 2002; Altman and Royston, 2006; Fitzsimons, 2008). We conducted an analysis of variance in which we entered Testosterone condition, median split Trait Dominance, and the Testosterone × Trait Dominance interaction as predictors of competitive decisions after victory. Replicating the results of prior analyses, there were no main effects but there was a statistically significant Testosterone Treatment × Trait Dominance interaction on competitive decisions after victory (F(1, 47) = 4.22, p = 0.046, \( \eta^2_{\text{partial}} = 0.08 \)) with a pattern highly consistent with the upper portion of Fig. 2 Column A (placebo treatment in high-dominant individuals: M = 57.73%, SE = 9.34; testosterone treatment in high-dominant individuals: M = 80.00%, SE = 11.44; placebo treatment in low-dominant individuals: M = 77.85%, SE = 10.44; testosterone treatment in low-dominant individuals: M = 57.01%, SE = 9.67).

We conducted a similar analysis for defeat trials. Testosterone condition, median split Trait Dominance scores, change in Positive Affect, and the Testosterone × Trait Dominance interaction were entered as predictors of competitive decisions after defeat. Consistent with the previous analyses and with the results shown in Figure 2, this analysis again revealed a main effect of Testosterone condition (F(1,46) = 5.24, \( p = 0.027 \), \( \eta^2_{\text{partial}} = 0.10 \)) such that testosterone administration (M = 43.86%, SE = 6.15) reduced competitive decisions after defeat compared to placebo administration (M = 63.72%, SE = 5.69), as well as a non-significant Testosterone × Trait Dominance interaction (F(1,46) = 0.68, p = 0.42). The pattern was consistent with the bottom portion of Fig. 2 Column A (placebo treatment in high-dominant individuals: M = 63.12%, SE = 7.50; testosterone treatment in high-dominant individuals: M = 36.55%, SE = 9.44; placebo treatment in low-dominant individuals: M = 64.32%, SE = 8.31; testosterone treatment in low-dominant individuals: M = 51.18%, SE = 7.63). These median split analyses corroborate the pattern of the Testosterone × Competition Outcome × Trait Dominance interaction on competitive decision-making obtained from the multilevel analyses and as shown in Fig. 2.

3.2.3. Competitive decisions after victory compared to defeat within individuals

Most prior correlational studies experimentally manipulated victory and defeat using between-subjects designs. The analyses reported above are consistent with the analysis approach used in these prior studies (e.g., Carré et al., 2009). The present experiment employed a within-subjects design to manipulate victory–defeat context in which participants won half of the competitions and lost on the other half. Hence, we conducted additional analyses in which we directly compared behavioral responses to victory and defeat trials within the same individual. More specifically, we tested whether competitive behavior after victory compared to defeat varied as a function of testosterone condition and trait dominance scores.

Based on the multilevel analyses (reported above), we conducted simple slopes tests (Aiken and West, 1991) for individuals one standard deviation above and below the mean on trait dominance. These analyses indicated that high-dominant participants (+1 SD) who were administered testosterone showed a greater tendency to compete again victory (78.94%) compared to defeat (42.47%) (\( b = 36.46, SE = 12.29, t(47) = 2.97, p = 0.005 \)), whereas high-dominant participants who were administered placebo did not significantly differ in their behavioral reactions to victory (47.03%) and defeat experience (63.63%) (\( b = −16.50, SE = 13.09, t(47) = 0.44, p = 0.664 \)). Low-dominant participants (−1 SD) in both the testosterone and placebo groups also showed non-significant differences in their behavioral responses to victory and defeat experience (\( p > 0.10 \)): low-dominant testosterone victory: 54.98% versus low-dominant placebo defeat: 60.70%; low-dominant placebo victory: 74.59% versus low-dominant placebo defeat: 74.01%

Collectively, these results indicate that testosterone administration increased the propensity to compete again after victory compared to defeat among high-dominant individuals.

To further investigate these within-individual effects, we also calculated the percentage of victory trials in which a participant chose to compete again minus the percentage of defeat trials in which the same participant chose to compete again. A positive score indicates a greater propensity to compete again after victory compared to defeat. We conducted a multiple-regression analysis in which we regressed this behavioral measure on to Change in Positive Affect, Testosterone condition, Trait Dominance (standardized), and the Testosterone × Trait Dominance interaction. Consistent with the previous analyses, this analysis revealed no main effects and a statistically significant Testosterone × Trait Dominance Interaction (\( b = 28.15, SE = 12.07, t(47) = 2.03, p = 0.05 \)). To interpret this interaction, the regression model slope estimates were used to plot percent of decisions to compete again after victory minus percentage of decisions to compete again after defeat scores as a function of testosterone and trait dominance (see Fig. 3). See also correlations reported in Table 5.

As shown in Fig. 3 and Table 5, there was a positive association between trait dominance and competitive behavior after victory compared to defeat in the testosterone group, but not in the placebo group. Follow-up simple slopes tests (Aiken and West, 1991) also revealed that compared to placebo treatment, testosterone treatment increased the propensity to compete again after victory relative to defeat among individuals high in trait dominance (+1 SD: \( b = 41.76, 95\% CI [1.61, 81.91], t(47) = 2.09, p < 0.05 \)) but not among individuals low in trait dominance (−1 SD: \( b = −15.86, 95\% CI [−55.95, 24.23], t(47) = −0.80, p = 0.43 \)). The pattern of results shown in Fig. 2 Column A indicates that testosterone’s causal influence on behavioral sensitivity to the prior victory–defeat experience was driven by both an increased propensity to compete again after victory and a decreased propensity to compete again after defeat in high-dominant individuals. These analyses further clarify the pattern of results shown in Fig. 2.
In summary, our main analyses revealed that the causal impact of testosterone on competitive decisions depended on the victory–defeat context and trait dominance. Testosterone increased competitive decisions after victory only among high-dominant individuals but testosterone decreased competitive decisions after defeat across all participants. We also found that testosterone enhanced the behavioral discrepancy between choosing to compete again after victory compared to defeat in high-dominant individuals.

3.3. Testosterone and opponent rank

Next we conducted follow-up exploratory analyses in which we examined the extent to which the experimental manipulation of opponent rank interacted with testosterone to influence competitive decisions. We conducted a moderated multilevel linear model analysis with trial types (Level 1) nested within participants (Level 2). The predictors were Opponent Rank (Lower-ranked, Same-ranked, or Higher-ranked Opponent) and Competition Outcome (Victory or Defeat) as within-subjects (Level 1) factors, along with the Level 2 factors of Testosterone condition (0 = placebo, 1 = testosterone) and Trait Dominance (centered), plus all interaction terms. The dependent variable was the percentage of trials in which participants chose to compete again (see Section 2.3 for rationale for this statistical approach). The full model is reported in the supplemental material (Table S1). This analysis revealed a main effect of Opponent Rank (b = −15.02, 95% CI [−21.22, −8.83], t(47) = −4.876, p < 0.001) and a marginally significant Opponent Rank × Competition Outcome interaction (b = 6.73, 95% CI [−0.79, 14.24], t(47) = 1.80, p = 0.078)\(^2\). As shown in Table 2, participants were more likely to compete against lower-ranked opponents followed by same-ranked followed by higher-ranked opponents. Participants were also more likely to compete after winning against a higher-ranked opponent compared to losing against a higher-ranked opponent. Crucially, the critical Testosterone × Competition Outcome × Trait Dominance interaction once again emerged in this follow-up analysis (b = 37.75, 95% CI [5.66, 69.83], t(47) = 2.37, p = 0.022), indicating that our primary result was robust to inclusion or exclusion of the Opponent Rank factor in the statistical model. There were no other significant effects in the model (non-significant interactions between Testosterone condition and Opponent Rank, p’s > 0.10). This analysis indicates that testosterone treatment selectively interacted with prior win–lose experience but not opponent social rank to influence competitive decision-making.

Even though there were non-significant interactions between testosterone and opponent rank, we conducted follow-up analyses in which we examined effects of testosterone on competitive decisions for each of the six trial types: defeat again lower-ranked, same-ranked, or higher-ranked opponents; victory against lower-ranked, same-ranked, or higher-ranked opponents. These analyses allowed us to confirm that testosterone’s behavioral effects reported above showed the same general pattern across opponent ranks. In each of these models we included positive affect change, Testosterone Condition, Trait Dominance, and the Testosterone × Trait Dominance as predictors of competitive decision-making. Results of these models can be found in the Supplementary material (Tables S2 and S3, see also Fig. 4). As shown in Table S2, there were statistically significant Testosterone × Trait Dominance interactions on competitive decisions after victory against lower-ranked opponents (b = 27.39, 95% CI [6.18, 48.60], t(46) = 2.599, p = 0.013) and same-ranked opponents (b = 23.97, 95% CI [1.83, 46.10], t(46) = 2.18, p = 0.034) with a similar but non-significant Testosterone × Trait Dominance interaction on competitive decisions after victory against higher-ranked opponents (b = 18.52, 95% CI [−4.73, 41.77], t(46) = 1.60, p = 0.116). As shown in Table S3 and Fig. 4, compared to placebo testosterone treatment reduced competitive decisions after defeat against lower-ranked (b = −19.36, 95% CI [−36.62, −2.10], t(46) = −2.26, p = 0.029) and same-ranked opponents (b = −20.34, 95% CI [−40.51, −0.18], t(46) = −2.03, p = 0.048) with a similar but non-significant pattern for defeat against higher-ranked opponents (b = −12.13, 95% CI [−33.99, 9.73], t(46) = −1.12, p = 0.270). These analyses indicate that the effects of testosterone treatment on competitive decision-making showed a similar pattern across opponent ranks.

3.4. Baseline testosterone

Baseline testosterone was uncorrelated with self-reported trait dominance scores (r = 0.01), and follow-up analyses revealed that baseline testosterone did not interact with the treatment condition, trait dominance, or competition outcome (victory versus defeat) to predict competitive decision-making (p’s > 0.10). Further, the
critical Testosterone × Competition Outcome × Trait Dominance interaction remained when controlling for baseline testosterone ($b = 29.63$, 95% CI [3.96, 55.29], $t(47) = 2.32$, $p = 0.025$). These analyses suggest that the main results of the present experiment cannot be accounted for by variability in baseline endogenous testosterone concentrations.

### 3.5. Beliefs about pharmacological manipulation

Twenty-one percent of participants in the testosterone group believed they received testosterone (the remaining participants believed they received placebo), and 19% participants in the placebo group through that they received testosterone (the remaining participants believe they received placebo), an effect indicating that participants’ guesses were no better than chance ($\chi^2(51) = 0.043$, $p = 0.84$). Further, follow-up analyses revealed that the Testosterone × Competition Outcome × Trait Dominance interaction emerged even when controlling for participants’ beliefs ($b = 29.63$, 95% CI [3.96, 55.29], $t(47) = 2.32$, $p = 0.025$). These analyses suggest that the main results reported here cannot be accounted for by beliefs about the pharmacological manipulation.

### 4. Discussion

The present experiment tested the causal influence of testosterone on human competitive decision-making. According to prevailing theories such as the challenge hypothesis, testosterone should directly boost competitive behaviors during periods of social competition. But correlational research in humans suggests that testosterone-behavior associations may depend on context and personality factors relevant to status (the win–lose context and trait dominance) (e.g., Mehta et al., 2008; Carré et al., 2009; Slatcher et al., 2011). Consistent with these recent correlational studies, this pharmacological experiment found that testosterone increased competitive decisions after victory only among high-dominant individuals but testosterone decreased competitive decisions after defeat across all participants. These effects of testosterone on competitive decision-making showed the same general pattern across opponent ranks.

These findings build upon a growing correlational literature in humans suggesting that testosterone taps into a person’s status-seeking motivation and alters reactivity to victory and defeat (Newman et al., 2005; Josephs et al., 2006; Mehta et al., 2008). Consistent with these correlational studies, exogenous testosterone may have increased competitive behavior after victory in high-dominant individuals because these individuals achieved a desirable high-status position and exhibited competitive behavior in order to reinforce their higher social standing and rise further within the dominance hierarchy (Mehta et al., 2008; Carré et al., 2009). In contrast, exogenous testosterone may have decreased competitive behavior after defeat because these individuals failed to achieve the higher status they desired, leading to heightened stress and a desire to avoid future competition against the same opponent in order to avoid further loss of status in the dominance hierarchy (Mehta et al., 2008; but see Mehta and Josephs, 2006; Carré et al., 2009). The findings suggest that testosterone boosts and inhibits competitive behavior depending on prior social experience (victory versus defeat) and a person’s dominance motivation in the service of enhancing one’s status.

These results are broadly consistent with non-human animal studies on the winner effect, which show that a combination of experimentally elevated testosterone and prior victory experience increases future aggressive and competitive behavior – behaviors that reinforce one’s higher social rank and encourage continued ascent in the status hierarchy (Trainor et al., 2004; Oliveira et al., 2009; Fußjager et al., 2010). Research in California mice shows that victory experiences increase the expression of androgen receptors in regions of the mesolimbic system implicated in dominance motivation and reward, including the nucleus accumbens (nACC) and the ventral tegmental area (VTA) (Fußjager et al., 2010). Testosterone influences dopamine release in the nACC (Packard et al., 1997), and this region is involved in aggressive and competitive behavior (cf. Fußjager et al., 2010). Human neuroimaging research also reveals effects of testosterone in the ventral striatum in response to monetary stimuli (Hermans et al., 2010). Hence, testosterone’s influence on post-victory competitive behavior observed in the present study may be driven by the reinforcing effects of dopamine in these motivational and reward regions of the mesolimbic pathway.

Testosterone treatment boosted post-victory competitive decisions only among individuals high in trait dominance, a pattern that converges with prior correlational research (Carré et al., 2009; see also Slatcher et al., 2011). Carré et al. (2009) found that endogenous testosterone interacted with trait dominance to predict men’s aggressive behavior in the victory condition of their experiment (a cognitive Number Tracking Task competition), and the pattern of the interaction was strikingly similar to that observed in the present experiment. This moderating effect of trait dominance on testosterone’s behavioral effects in both experimental and correlational studies aligns well with mechanisms involving the mesolimbic system discussed above. Indeed, dominance is a personality trait that emerges across species and is related to attaining higher status (Johnson et al., 2012; Favati et al., 2014). Dopaminergic activity in the central nervous system correlates with trait dominance in monkeys (Kaplan et al., 2002), and dopamine receptor availability in the ventral striatum is correlated with status in humans (Martínez et al., 2010). These results suggest that high-dominant individuals may show a testosterone-dependent winner effect due to enhanced androgen sensitivity in the mesolimbic system.

The finding that exogenous testosterone reduced competitive behavior after defeat across the entire sample conceptually replicates a prior correlational study, which found that higher endogenous testosterone in females was associated with a reduced desire to compete after defeat on a cognitive Number Tracking Task (Mehta et al., 2008). The present findings taken together with these prior correlational results are consistent with evidence that testosterone enhances sensitivity to status threats. High basal testosterone predicts aversive reactions to social defeat, including increased negative affect, increased activity in the neuroendocrine stress axis, hyper-attention to status threat cues, and impaired performance on complex cognitive tasks (Newman et al., 2005; Josephs et al., 2006; Mehta et al., 2008; Terburg et al., 2012; Zilioli and Watson, 2013; see also Enter et al., 2014). Testosterone is also related to enhanced amygdala and hypothalamus activity (Hermans et al., 2008; Goetz et al., 2014; Radke et al., 2015), reduced orbitofrontal cortex activity (Mehta and Beer, 2010), and disrupted amygdala–prefrontal cortex connectivity in response to status threats (van Wingen et al., 2010; Volman et al., 2011). Further, recent evidence suggests that testosterone has context-dependent effects on amygdala responses to dominance threat cues (angry faces): testosterone treatment increased amygdala activity during threat approach but decreased it during social threat avoidance (Radke et al., 2015). Together, these findings suggest that testosterone may heighten negative affect and inhibit competitive behavior after defeat alterations within this subcortical–prefrontal network, a hypothesis that warrants further research.

The present findings may help clarify the causal role of testosterone on a range of social behaviors. Indeed, the few human studies that investigated the effects of exogenous testosterone on other status–relevant behaviors such as aggression or bargaining behavior have found some null and inconsistent effects (see review by
Eisenegger et al., 2011), but these studies did not take into account win–lose experience or trait dominance. Thus, it is plausible that the context- and person-dependent effects of testosterone identified in the present research may extend beyond competitive decision-making to additional status-relevant behaviors.

There are some limitations to the present experiment and open questions that should be addressed in future studies. First, we recruited healthy women who were taking hormonal contraceptives in order to control for potential fluctuations in testosterone concentrations across the menstrual cycle, but there was heterogeneity in the type of contraceptives that women were using. The present experiment did not have sufficient statistical power to test whether testosterone's behavioral effects varied as a function of hormonal contraceptive type, but this question should be addressed in future studies. A second limitation is that it is unclear whether the present results will extend to women who are not on hormonal contraceptives. Future research is needed to test the behavioral effects of exogenous testosterone in normally cycling women across different phases of the menstrual cycle. Third, it remains unknown whether the current findings will be observed in men. Some research has shown similar effects of testosterone treatment in males and females (e.g., Hermans et al., 2008; Goetz et al., 2014), but other studies suggest that there could be sex differences in the behavioral effects of exogenous testosterone (e.g., Eisenegger et al., 2009; Zak et al., 2009). Future research will be required to test whether testosterone's effects on competitive decision-making shows similarities or differences across males and females. And finally, due to the novelty of the findings it is important to conduct conceptual replications using both correlational and experimental designs.

In summary, the present experiment is the first to test the causal impact of testosterone on human competitive decision-making. We found that exogenous testosterone increased competitive decisions after victory only among high-dominant individuals but testosterone decreased competitive decisions after defeat across all participants. These results expand theories of testosterone's role in the pursuit of social status (Winfield et al., 1990; Mazur and Booth, 1998; Archer, 2006) and open up new avenues for research on context- and person-dependent effects of exogenous testosterone on human behavior. We documented these effects of testosterone in a sample of females taking hormonal contraceptives, but future research is needed to determine whether similar results emerge in normally cycling women and in males.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.psyneuen.2015.07.004

References


